RESUMO
An open label, comparative study to compare the efficacy of thermotherapy to meglumine antimoniate in treating cutaneous leishmaniasis patients in an operational context was carried out in Chaparral, Colombia. After enrollment patients were followed-up for up to 100 days. Per protocol and intention-to-treat cure rates for 47 patients treated using thermotherapy (one-time 50 degrees C applications for 30s) were 100 and 19%, respectively. Per protocol and intention-to-treat cure rates for meglumine antimoniate (20 mg/kg body weight administered intramuscularly for 21 d) were 78 and 23%, respectively.
Assuntos
Antiprotozoários/uso terapêutico , Hipertermia Induzida/métodos , Leishmaniose Cutânea/terapia , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Adolescente , Adulto , Antiprotozoários/economia , Criança , Pré-Escolar , Colômbia , Feminino , Humanos , Lactente , Recém-Nascido , Leishmaniose Cutânea/diagnóstico , Leishmaniose Cutânea/economia , Masculino , Meglumina/economia , Antimoniato de Meglumina , Compostos Organometálicos/economia , Estudos Prospectivos , Resultado do Tratamento , Adulto JovemRESUMO
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).